Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug
- 5 February 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Delivery
- Vol. 5 (2) , 205-219
Abstract
(2008). Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opinion on Drug Delivery: Vol. 5, No. 2, pp. 205-219. doi: 10.1517/17425247.5.2.205Keywords
This publication has 75 references indexed in Scilit:
- Pulsed-High Intensity Focused Ultrasound and Low Temperature–Sensitive Liposomes for Enhanced Targeted Drug Delivery and Antitumor EffectClinical Cancer Research, 2007
- VEGF-A and the Induction of Pathological AngiogenesisAnnual Review of Pathology: Mechanisms of Disease, 2007
- Biomimetic amplification of nanoparticle homing to tumorsProceedings of the National Academy of Sciences, 2007
- A Bacterial Protein Enhances the Release and Efficacy of Liposomal Cancer DrugsScience, 2006
- Polymer conjugates as anticancer nanomedicinesNature Reviews Cancer, 2006
- Low and high molecular weight poly(l‐lysine)s/poly(l‐lysine)–DNA complexes initiate mitochondrial‐mediated apoptosis differentlyFEBS Letters, 2005
- Block copolymer micelles as a solution for drug delivery problemsExpert Opinion on Therapeutic Patents, 2005
- Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancerAnti-Cancer Drugs, 2003
- Pharmacokinetics of Pegylated Liposomal DoxorubicinClinical Pharmacokinetics, 2003
- Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugsJournal of Controlled Release, 2002